April 2007

	Start-Up: In RNAi, Technology Proliferates Beyond the Big Two	[Read Summary]	[Buy Article]
	The RPM Report: Timing is Everything: Biotech Pioneers Push Follow-On Biologics Proposal	[Read Summary]	[Buy Article]
	The RPM Report: Trontell Embodies AHRQ-FDA Co-sponsorship of CERTs	[Read Summary]	[Buy Article]
	The RPM Report: CERTs Look to Re-Assert Larger Role in Post-Marketing Surveillance	[Read Summary]	[Buy Article]
	The RPM Report: Good Predictions: FDA Encouraged by Biomarker Progress	[Read Summary]	[Buy Article]
	The RPM Report: Nervous Times for NDA Sponsors: The New Reality of FDA Drug Reviews	[Read Summary]	[Buy Article]

March 2007

	In Vivo: OrthoMEMS: Measuring What Matters in Spine	[Read Summary]	[Buy Article]
	In Vivo: Januvia: Defining Primary-Care Success and Risk	[Read Summary]	[Buy Article]
	In Vivo: GE Grabs the Spotlight in IVD	[Read Summary]	[Buy Article]
	In Vivo: Payback II: Medical Devices Ride the Cash Curve	[Read Summary]	[Buy Article]
	In Vivo: CoreValve: A Surgeon Moves Heart Valves to the Cath Lab	[Read Summary]	[Buy Article]
	In Vivo: Proteus Biomedical: Using Computers to Manage Chronic Diseases	[Read Summary]	[Buy Article]
	Start-Up: Early Development Firms Set the Stage for Medical Devices	[Read Summary]	[Buy Article]
	Start-Up: Venture Philanthropy: The New Venture Capital?	[Read Summary]	[Buy Article]
	The RPM Report: Can Prevnar Get to $3 Billion Per Year?	[Read Summary]	[Buy Article]
	The RPM Report: Tilting the Contracting Scales: Part D Plans Have Advantages Over Manufacturers in 2008	[Read Summary]	[Buy Article]
	The RPM Report: A Day Late and a Billion Dollars Short: TMC's Angiomax Patent Nightmare	[Read Summary]	[Buy Article]
	The RPM Report: The Politics of Drug Safety: An FDA Whistleblower's Push for Reform	[Read Summary]	[Buy Article]
	The RPM Report: Powerful Safety Tools: Use With Caution	[Read Summary]	[Buy Article]
	The RPM Report: Signals of FDA Movement on Advanced Signal Detection	[Read Summary]	[Buy Article]
	The RPM Report: Refining Data Mining: Taking Control of a Powerful New Tool	[Read Summary]	[Buy Article]

February 2007

	In Vivo: In Women's Health, Hologic Stays Ahead of the Curve	[Read Summary]	[Buy Article]
	In Vivo: NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?	[Read Summary]	[Buy Article]
	In Vivo: Pfizer Gets Closer to Customers	[Read Summary]	[Buy Article]
	In Vivo: Strength in Spine	[Read Summary]	[Buy Article]
	In Vivo: ev3: The Virtues of Focus	[Read Summary]	[Buy Article]
	In Vivo: Drug Delivery Heats Up	[Read Summary]	[Buy Article]
	Start-Up: The Climate for Investing in Platform Technologies	[Read Summary]	[Buy Article]
	Start-Up: Embracing Early-Stage Platform Opportunities at Polaris Ventures	[Read Summary]	[Buy Article]
	Start-Up: Where are They Now? Yesterday's Stroke Companies	[Read Summary]	[Buy Article]
	The RPM Report: Roche's New EPO: "White Knight" or Wolf in Sheep's Clothing?	[Read Summary]	[Buy Article]
	The RPM Report: Putting the Bully in the Bully Pulpit: The Democrats' Plan to Cut Drug Prices	[Read Summary]	[Buy Article]
	The RPM Report: The Power of the Purse: FDA Seeks More Money, Not More Authority	[Read Summary]	[Buy Article]

January 2007

	In Vivo: Krauth Medical: Finding a Way in the New German Market	[Read Summary]	[Buy Article]
	In Vivo: Novasys: Using Clinical Trials to Drive Adoption for Incontinence	[Read Summary]	[Buy Article]
	In Vivo: The Guidant Legacy: An Interview with Ron Dollens	[Read Summary]	[Buy Article]
	In Vivo: Headlines Obscure Robust Year for Devices in 2006	[Read Summary]	[Buy Article]
	In Vivo: A Look Back at 2006: The Pipeline Challenge	[Read Summary]	[Buy Article]
	In Vivo: Specialty Pharma: Tapping Japan	[Read Summary]	[Buy Article]
	The RPM Report: McClellan's FDA Team	[Read Summary]	[Buy Article]
	The RPM Report: Can You Hear That Whistle Blow? Sales Force Reductions Come with Risks	[Read Summary]	[Buy Article]
	The RPM Report: Too Many Doses? Or the Road to Universal Vaccination?	[Read Summary]	[Buy Article]
	The RPM Report: Nice Recovery: Protecting the Vaccine Market	[Read Summary]	[Buy Article]
	The RPM Report: Reinventing Pharmacy: The Bidding for Caremark is Just the Beginning	[Read Summary]	[Buy Article]
	The RPM Report: Fair Balance: Kennedy-Enzi Wins Praise for Warning Labels	[Read Summary]	[Buy Article]
	The RPM Report: Flying Blind: Learning to Live Without Physician Prescribing Data	[Read Summary]	[Buy Article]
	The RPM Report: FDA's Drug Safety Changes: Safe Legislation; Unsafe Climate	[Read Summary]	[Buy Article]

December 2006

	In Vivo: Innovation in Cardiology--and Beyond.	[Read Summary]	[Buy Article]
	In Vivo: The Acomplia Paradox: Primary Care Drug, Targeted Population	[Read Summary]	[Buy Article]
	In Vivo: FDA's Drug Safety Changes: Safe Legislation; Unsafe Climate	[Read Summary]	[Buy Article]
	In Vivo: Reliant: The Expensive Opportunities in Primary Care	[Read Summary]	[Buy Article]
	In Vivo: InnerPulse: Bringing the Interventional Revolution to CRM	[Read Summary]	[Buy Article]
	In Vivo: BioAssets: Convergence as Marketing Play	[Read Summary]	[Buy Article]
	Start-Up: Bifurcation Stenting: The Next Generation	[Read Summary]	[Buy Article]
	Start-Up: Molecular Origami: Start-Ups Tackle Protein Folding	[Read Summary]	[Buy Article]
	The RPM Report: Finding a Successor to AWP	[Read Summary]	[Buy Article]
	The RPM Report: Risky Business	[Read Summary]	[Buy Article]
	The RPM Report: Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn	[Read Summary]	[Buy Article]
	The RPM Report: The Name of the Game: Adjusting to a Tougher FDA Brand Name Review Process	[Read Summary]	[Buy Article]
	The RPM Report: Follow the Money: Why the Democrats Won't Kill Private Medicare Plans	[Read Summary]	[Buy Article]
	The RPM Report: Negotiating Price Negotiation: Why the Democrats Will Struggle to Pressure Part D Prices	[Read Summary]	[Buy Article]

November 2006

	In Vivo: Satiety: Treating Obesity Beyond Quality of Life	[Read Summary]	[Buy Article]
	In Vivo: Tornier: Building an Extremities Play in Orthopedics	[Read Summary]	[Buy Article]
	In Vivo: Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy	[Read Summary]	[Buy Article]
	In Vivo: Novartis' M&A Machine	[Read Summary]	[Buy Article]
	In Vivo: The $100 Million IND	[Read Summary]	[Buy Article]
	In Vivo: Genzyme Breaks a Biotech Taboo: The Hostile Bid For AnorMED	[Read Summary]	[Buy Article]
	Start-Up: TransDerm Inc.	[Read Summary]	[Buy Article]
	Start-Up: Moving Beyond Accutane and Botox	[Read Summary]	[Buy Article]
	Start-Up: The IP Land Grab: New UK Tech Transfer Models	[Read Summary]	[Buy Article]
	Start-Up: Lung Cancer: An Up and Coming Device Market	[Read Summary]	[Buy Article]
	The RPM Report: One Small Step for FDA...	[Read Summary]	[Buy Article]
	The RPM Report: Designer Labeling: Drug Safety Reform Proposals Include New Powers for FDA	[Read Summary]	[Buy Article]
	The RPM Report: The Part D Bubble: Why Everyone Wants to be a PDP	[Read Summary]	[Buy Article]
	The RPM Report: The Next Coverage Hurdle: Pharmacogenomics as Formulary Control Tool	[Read Summary]	[Buy Article]
	The RPM Report: Competing Priorities: Alzheimer's Drugs and the Delicate Balance that Defines Part D	[Read Summary]	[Buy Article]

October 2006

	In Vivo: Turning Around Medtronic Vascular	[Read Summary]	[Buy Article]
	In Vivo: In the Eye of the Storm	[Read Summary]	[Buy Article]
	In Vivo: Oakes, Lyman: Is This the Model for Building European Device Companies?	[Read Summary]	[Buy Article]
	In Vivo: Pharma's Innovation Bar and the Need for Less Impersonal Medicine	[Read Summary]	[Buy Article]
	In Vivo: European Consolidation: Serious Competition for Big Pharma?	[Read Summary]	[Buy Article]
	Start-Up: IPO Failures Can Set Up Biotech Successes	[Read Summary]	[Buy Article]
	Start-Up: The Creative Mind of Yossi Gross, Medical Device Inventor	[Read Summary]	[Buy Article]
	Start-Up: Diamics Inc.	[Read Summary]	[Buy Article]
	Start-Up: Women's Health: A Growing Market for Diagnostic Players	[Read Summary]	[Buy Article]
	The RPM Report: The War on Generics - Part II	[Read Summary]	[Buy Article]
	The RPM Report: Still Room in Big Market for Small Companies?	[Read Summary]	[Buy Article]
	The RPM Report: Flu Speed Ahead in Vaccines Market	[Read Summary]	[Buy Article]
	The RPM Report: Evidence-based Medicine Pioneers	[Read Summary]	[Buy Article]
	The RPM Report: Collaborating With Payors on Clinical Trials	[Read Summary]	[Buy Article]
	The RPM Report: CSL's Shortcut from Down Under	[Read Summary]	[Buy Article]

September 2006

	In Vivo: Evalve: Leading the Valve Revolution	[Read Summary]	[Buy Article]
	In Vivo: Generic Plavix: As Bristol Swoons, Broad Implications	[Read Summary]	[Buy Article]
	In Vivo: The Rise of Regional Dealmaking	[Read Summary]	[Buy Article]
	In Vivo: In Devices, Abbott Bulks Up: An Interview with Rick Gonzalez	[Read Summary]	[Buy Article]
	In Vivo: Stryker: The New Dealmakers in Orthopedics	[Read Summary]	[Buy Article]
	In Vivo: The Outsourcing Dilemma	[Read Summary]	[Buy Article]
	Start-Up: Where Are They Now?	[Read Summary]	[Buy Article]
	Start-Up: Devices for a Diabetes Epidemic	[Read Summary]	[Buy Article]
	The RPM Report: The Three Engines Driving the Vaccine Resurgence	[Read Summary]	[Buy Article]
	The RPM Report: The End of Buy-and-Bill?	[Read Summary]	[Buy Article]
	The RPM Report: Novartis/Chiron: Validating the Value of Vaccine R&D	[Read Summary]	[Buy Article]
	The RPM Report: Government Funding and the Push/Pull Engine	[Read Summary]	[Buy Article]
	The RPM Report: Gardasil Pushes Vaccine Prices--and Markets--to New Heights	[Read Summary]	[Buy Article]
	The RPM Report: The War on Generics - Part I	[Read Summary]	[Buy Article]
	The RPM Report: Editor's Letter	[Read Summary]	[Buy Article]
	The RPM Report: A Word to the Wise as Managed Care Enters Rx Communicaiton	[Read Summary]	[Buy Article]
	The RPM Report: Vaccines Enter the New Age of Adjuvants	[Read Summary]	[Buy Article]

July 2006

	In Vivo: Edwards Lifesciences: Staking New Ground in Cardiovascular Devices	[Read Summary]	[Buy Article]
	In Vivo: NxStage: Bringing Dialysis Home	[Read Summary]	[Buy Article]
	In Vivo: Intuitive Surgical: Making Robotics Real	[Read Summary]	[Buy Article]
	In Vivo: Big Pharma's Secret Weapon	[Read Summary]	[Buy Article]
	In Vivo: Why EPO Matters	[Read Summary]	[Buy Article]
	In Vivo: How Pharma Can Cope with Consumerism	[Read Summary]	[Buy Article]
	The RPM Report: Part D Glue Is Holding	[Read Summary]	[Buy Article]
	The RPM Report: Critical Collaborators	[Read Summary]	[Buy Article]
	The RPM Report: Welcome to the P&T Committee: Reining in Biotech Prices	[Read Summary]	[Buy Article]
	The RPM Report: Big Pharma's Secret Weapon: Medicare Starts to Pay Off-Quietly	[Read Summary]	[Buy Article]
	The RPM Report: The Second Coming: Tysabri Ready For Blockbuster Status?	[Read Summary]	[Buy Article]
	The RPM Report: Editor's Letter: July 2006	[Read Summary]	[Buy Article]
	The RPM Report: Playing Doctor: The Impact of the Tysabri Risk Plan	[Read Summary]	[Buy Article]
	The RPM Report: Tsunami Economics: The Wave is Coming	[Read Summary]	[Buy Article]
	The RPM Report: Man Who Signs On Dotted Line	[Read Summary]	[Buy Article]
	The RPM Report: Donut Hole Politics: Patient Assistance Under Part D	[Read Summary]	[Buy Article]

June 2006

	In Vivo: Biopharma: Beyond the First Product	[Read Summary]	[Buy Article]
	In Vivo: Richard Stack, MD: Filling the Cath Lab Pipeline	[Read Summary]	[Buy Article]
	In Vivo: Synecor's Golden Touch	[Read Summary]	[Buy Article]
	In Vivo: Medicare Part B vs. Part D	[Read Summary]	[Buy Article]
	In Vivo: Abiomed: Heart Recovery, Not Replacement	[Read Summary]	[Buy Article]
	In Vivo: The Large Molecule Future	[Read Summary]	[Buy Article]
	Start-Up: Tapping the Potential of Atrial Fibrillation Devices	[Read Summary]	[Buy Article]
	Start-Up: The Price is Wrong: Finding Alternatives to Traditional IPOs	[Read Summary]	[Buy Article]
	The RPM Report: Mind Your Bs and Ds	[Read Summary]	[Buy Article]
	The RPM Report: Pharma's Patience Pays Off: Patient Advocates Are Powerful Allies in Part D	[Read Summary]	[Buy Article]
	The RPM Report: Medicare Formulary Rules Add Bite to "Black Box" Warnings	[Read Summary]	[Buy Article]
	The RPM Report: Too Many Middlemen? Long-Term Care Pharmacies are Losing Fight for Control of Part D Formularies	[Read Summary]	[Buy Article]
	The RPM Report: Anything but Academic: Lessons From the PPAR Failures	[Read Summary]	[Buy Article]
	The RPM Report: A CERA-ous Challenge to Amgen's EPO Franchise?	[Read Summary]	[Buy Article]

May 2006

	In Vivo: The Power of Perseverance	[Read Summary]	[Buy Article]
	In Vivo: Pathway Medical: Pursuing the Hawk	[Read Summary]	[Buy Article]
	In Vivo: Forced to Act: Omnitrope and the Battle for an FDA Commissioner	[Read Summary]	[Buy Article]
	In Vivo: Elekta: Growing from the Head Down	[Read Summary]	[Buy Article]
	In Vivo: Novartis's Research Experiment	[Read Summary]	[Buy Article]
	In Vivo: Molecular Diagnostics--From Tools to Tests	[Read Summary]	[Buy Article]
	Start-Up: The Knee Market Begins to Bend for Start-Ups	[Read Summary]	[Buy Article]
	Start-Up: Amorfix Life Sciences Ltd.	[Read Summary]	[Buy Article]
	Start-Up: Alzheimer's Disease Diagnostics	[Read Summary]	[Buy Article]
	Start-Up: Stem Cells: What's the Business Model?	[Read Summary]	[Buy Article]
	The RPM Report: Clear Messages From Part D: Managed Care Learns to Work With Retail Pharmacists	[Read Summary]	[Buy Article]
	The RPM Report: Map To FDA RiskMAPs	[Read Summary]	[Buy Article]
	The RPM Report: The Dubai Effect	[Read Summary]	[Buy Article]
	The RPM Report: Time to Pay the Piper? Industry Prepares for a Fight Over User Fees	[Read Summary]	[Buy Article]
	The RPM Report: Forced to Act: Omnitrope and the Battle for an FDA Commissioner	[Read Summary]	[Buy Article]

April 2006

	In Vivo: Drug Safety Reform: Did FDA Buy Time or Trouble?	[Read Summary]	[Buy Article]
	In Vivo: ArthroCare's Next Act	[Read Summary]	[Buy Article]
	In Vivo: InfraReDx: Saved by Angels (and a VC)	[Read Summary]	[Buy Article]
	In Vivo: Endosense: Growing Up Fast in AF	[Read Summary]	[Buy Article]
	In Vivo: Why Products Fail in Phase III	[Read Summary]	[Buy Article]
	In Vivo: Shire: Remodeling Specialty Pharma	[Read Summary]	[Buy Article]
	Start-Up: Remote Patient Monitoring: The Markets Near and Far	[Read Summary]	[Buy Article]
	Start-Up: TheraPei Pharmaceuticals Inc.	[Read Summary]	[Buy Article]
	Start-Up: Investing in India and China	[Read Summary]	[Buy Article]
	Start-Up: Profiles of Two Iconoclasts	[Read Summary]	[Buy Article]
	The RPM Report: The "Other" IoM Drug Safety Committee	[Read Summary]	[Buy Article]
	The RPM Report: FDA's Consumer Ad Watchdogs	[Read Summary]	[Buy Article]
	The RPM Report: Tysabri: The Risk of Revival	[Read Summary]	[Buy Article]
	The RPM Report: Drug Safety Reform: Did FDA Buy Time or Trouble?	[Read Summary]	[Buy Article]

March 2006

	In Vivo: Nothing Random About It: The State of Cancer Drug Development at FDA	[Read Summary]	[Buy Article]
	In Vivo: Cyberonics' Two-Front War	[Read Summary]	[Buy Article]
	In Vivo: St. Francis Medical: Staking Ground in Dynamic Stabilization	[Read Summary]	[Buy Article]
	In Vivo: OrbusNeich: Tissue Engineering Meets Coronary Stents	[Read Summary]	[Buy Article]
	In Vivo: Tramadol Reformulations Highlight Pain Challenges and Opportunities	[Read Summary]	[Buy Article]
	In Vivo: GSK's Risk-Sharing Deals to Compete with In-House R&D	[Read Summary]	[Buy Article]
	Start-Up: The Cardio-Renal Connection	[Read Summary]	[Buy Article]
	Start-Up: Pandemic Preparedness	[Read Summary]	[Buy Article]
	Start-Up: The New Diagnostics Companies	[Read Summary]	[Buy Article]
	The RPM Report: Booz Allen Inside	[Read Summary]	[Buy Article]
	The RPM Report: Medicare's Privileged Drug Classes: Price Protections Through 2007	[Read Summary]	[Buy Article]
	The RPM Report: Nothing Random About It: The State of Cancer Drug Development at FDA	[Read Summary]	[Buy Article]

February 2006

	In Vivo: The Approval Drought	[Read Summary]	[Buy Article]
	In Vivo: Rita Medical: Can a Device Pure Play Compete in Oncology?	[Read Summary]	[Buy Article]
	In Vivo: X-Cell Medical: Putting Safety First	[Read Summary]	[Buy Article]
	In Vivo: EndoGastric Solutions: Re-Inventing GERD Therapy	[Read Summary]	[Buy Article]
	In Vivo: Insomnia: Pharma Wakes Up to the Next Huge CNS Market	[Read Summary]	[Buy Article]
	In Vivo: Anatomy of a Deal: Inside the AstraZeneca/ AtheroGenics Agreement	[Read Summary]	[Buy Article]
	Start-Up: ADMETRx	[Read Summary]	[Buy Article]
	Start-Up: The Next-Generation Antibody Players	[Read Summary]	[Buy Article]
	Start-Up: An Early Peek at Glaucoma Devices	[Read Summary]	[Buy Article]
	The RPM Report: Fashionably Early: When to Make Your Case to CMS	[Read Summary]	[Buy Article]
	The RPM Report: A Critical Test for FDA's Critical Path Initiative	[Read Summary]	[Buy Article]
	The RPM Report: FDA Critical Path Relies on Arizona Institute	[Read Summary]	[Buy Article]

January 2006

	In Vivo: Medtronic: Making Convergence Pay	[Read Summary]	[Buy Article]
	In Vivo: CardioMind: Big Solutions to Small Problems	[Read Summary]	[Buy Article]
	In Vivo: Reviewing 2005: The Top Medical Device Stories	[Read Summary]	[Buy Article]
	In Vivo: Acclarent: Can Balloons Open Sinuses and the ENT Device Market?	[Read Summary]	[Buy Article]
	In Vivo: Reviewing 2005: The Top Biopharma Stories	[Read Summary]	[Buy Article]
	In Vivo: How Biopharma Can Flourish in a Deteriorating Environment	[Read Summary]	[Buy Article]
	Start-Up: NuPathe Inc.	[Read Summary]	[Buy Article]
	Start-Up: NeurAxon Inc.	[Read Summary]	[Buy Article]
	Start-Up: Addex Pharmaceuticals SA	[Read Summary]	[Buy Article]
	Start-Up: Migraine--Moving Beyond Triptans	[Read Summary]	[Buy Article]
	The RPM Report: Investigating FDA	[Read Summary]	[Buy Article]
	The RPM Report: Formulary 101: The Medicare Program Hosts A Cash Course In Therapeutic Alternatives	[Read Summary]	[Buy Article]
	The RPM Report: Biogenerics Are Happening: Slowly, Product-By-Product	[Read Summary]	[Buy Article]
	The RPM Report: Building a Business in Drug Safety	[Read Summary]	[Buy Article]

December 2005

	In Vivo: Building Billion-Dollar Businesses: An Interview with Robert Croce	[Read Summary]	[Buy Article]
	In Vivo: Labcoat: Less is more in Next Generation Drug-Eluting Stents	[Read Summary]	[Buy Article]
	In Vivo: Hep C Development Dilemma: Big Money Now or Bigger Money Later?	[Read Summary]	[Buy Article]
	In Vivo: Edwards: Battling the Innovator's Dilemma	[Read Summary]	[Buy Article]
	In Vivo: Cephalon: Can Spec Pharma do R&D?	[Read Summary]	[Buy Article]
	Start-Up: Nothing Ventured, Something Gained	[Read Summary]	[Buy Article]
	Start-Up: The New Out-Licensing Start-Ups: Securing Product Supply	[Read Summary]	[Buy Article]
	Start-Up: DiaKine Therapeutics Inc.	[Read Summary]	[Buy Article]
	Start-Up: Biotechs Brace to Battle a Deadly GI Bacterium	[Read Summary]	[Buy Article]
	The RPM Report: DTC Loses Powerful Friends, Will PhRMA Bring Them Back?	[Read Summary]	[Buy Article]
	The RPM Report: CATIE: Learning to Live With large Comparative Trials	[Read Summary]	[Buy Article]

November 2005

	In Vivo: The HPV Vaccine Race	[Read Summary]	[Buy Article]
	In Vivo: TranS1:Transcending the Surgeon/Rep/Relationship	[Read Summary]	[Buy Article]
	In Vivo: Shining the Light on a Combination Products Platform	[Read Summary]	[Buy Article]
	In Vivo: Leveraging Patient-Centric Information for Market Success	[Read Summary]	[Buy Article]
	In Vivo: Positioning Acomplia: Has the Drug Arrived Before the Disease?	[Read Summary]	[Buy Article]
	Start-Up: Gauging the Risks of Financing Convergence Start-Ups	[Read Summary]	[Buy Article]
	Start-Up: The Farsightedness of Refractec	[Read Summary]	[Buy Article]

October 2005

	In Vivo: LipoSonix: Addition by Subtraction	[Read Summary]	[Buy Article]
	In Vivo: Volcano's Second Act	[Read Summary]	[Buy Article]
	In Vivo: Lilly Stands Firm Against Florida Price Negotiations	[Read Summary]	[Buy Article]
	In Vivo: Pfizer's Exubera: Breathing New Life Into Inhaled Insulin	[Read Summary]	[Buy Article]
	Start-Up: Gastroenterology's Elusive Device Opportunity	[Read Summary]	[Buy Article]
	Start-Up: Novartis Opens Door to Broad Dealmaking in RNAi	[Read Summary]	[Buy Article]

September 2005

	In Vivo: Show Me the Money: Why Companies Overpay MCOs--and How They Can Stop	[Read Summary]	[Buy Article]
	In Vivo: No Dilution Necessary: The Promise of Project Financing	[Read Summary]	[Buy Article]
	In Vivo: KCI: In Wound Care, A Surfaces Company Goes Deep	[Read Summary]	[Buy Article]
	In Vivo: Gyrus and ACMI--A Great Marriage, But What's Next?	[Read Summary]	[Buy Article]
	In Vivo: Northstar's Buzz	[Read Summary]	[Buy Article]
	In Vivo: Biosimilars: EMEA Wants Approvals	[Read Summary]	[Buy Article]
	Start-Up: The Health of Device Start-Ups: An Interview with Peter Fitzgerald	[Read Summary]	[Buy Article]
	Start-Up: Trade Sales Trump IPOs, Even for Platforms	[Read Summary]	[Buy Article]

July 2005

	In Vivo: Feeding the Beast: Steady M&A Diet Fuels VAlue for Big Device Firms	[Read Summary]	[Buy Article]
	In Vivo: Cardio3: Moving from Science Project to Business Model in Stem Cells	[Read Summary]	[Buy Article]
	In Vivo: Novation's Play in Physician-Preferred Products	[Read Summary]	[Buy Article]
	In Vivo: Hurry Up and Wait: The Slowdown in Accelerated Approvals	[Read Summary]	[Buy Article]
	In Vivo: Smith & Nephew's Race to the Top	[Read Summary]	[Buy Article]
	In Vivo: Pfizer-Vicuron: Fill Pipeline, Minimize R&D Expense	[Read Summary]	[Buy Article]

June 2005

	In Vivo: Getting a Grip on Oncology Drug Costs--and Pricing	[Read Summary]	[Buy Article]
	In Vivo: Curis Reformed: Unearthing Preclinical Value	[Read Summary]	[Buy Article]
	In Vivo: Hemoteq's Fancy New Coat	[Read Summary]	[Buy Article]
	In Vivo: Beyond Medical Devices: An Interview with Medtronic's Bill Hawkins	[Read Summary]	[Buy Article]
	In Vivo: Pierre Fabre: Time to Reap R&D Rewards In-House	[Read Summary]	[Buy Article]
	In Vivo: Neurometrix Hits a Nerve in the Diabetes Market	[Read Summary]	[Buy Article]
	Start-Up: Choose One, Not Both: Why Balanced Biopharma Funds Stumble	[Read Summary]	[Buy Article]
	Start-Up: Grad School for Device Entrepreneurs	[Read Summary]	[Buy Article]

May 2005

	In Vivo: Changing Italian Hospital Distribution: NGC Assumes Risk to Gain Reward	[Read Summary]	[Buy Article]
	In Vivo: Texas Back Institute: Spine's Technology Laboratory	[Read Summary]	[Buy Article]
	In Vivo: A Little Knowledge: The FDA's Public Approach to Safety	[Read Summary]	[Buy Article]
	In Vivo: Making Licensing Pay	[Read Summary]	[Buy Article]
	In Vivo: DTC Advertising Under Pressure	[Read Summary]	[Buy Article]
	In Vivo: European Biotech Is Specialty Pharma	[Read Summary]	[Buy Article]
	Start-Up: Scratch-Free Skin Resurfacing	[Read Summary]	[Buy Article]
	Start-Up: Glycobiology's Second Wave	[Read Summary]	[Buy Article]

April 2005

	In Vivo: Lilly's Transparency Strategy	[Read Summary]	[Buy Article]
	In Vivo: Problems With Biomarkers: A Tale of Three Drugs	[Read Summary]	[Buy Article]
	In Vivo: Going Out With a Bang--An Interview with Ron Dollens	[Read Summary]	[Buy Article]
	In Vivo: IST: The Big Bang Theory of Device Innovation	[Read Summary]	[Buy Article]
	In Vivo: Inion: Making Orthopedic Implants Fade Away	[Read Summary]	[Buy Article]
	In Vivo: Novartis/Hexal: Generic Consolidation, and More	[Read Summary]	[Buy Article]
	Start-Up: Breaking the Surgical Adhesion Barrier	[Read Summary]	[Buy Article]
	Start-Up: The Challenge of Making Money from Biomarkers	[Read Summary]	[Buy Article]

March 2005

	In Vivo: Ars Arthro: Taking Tissue Engineering one Step at a Time	[Read Summary]	[Buy Article]
	In Vivo: View From the Cath Lab: Hot Issues in Cardiology	[Read Summary]	[Buy Article]
	In Vivo: Ekos' Long, Hard Road	[Read Summary]	[Buy Article]
	In Vivo: Theravance: Having Cake and Eating It	[Read Summary]	[Buy Article]
	In Vivo: German Biotech: Coalescing around the Haves	[Read Summary]	[Buy Article]
	In Vivo: Making Clinical Trials More Efficient	[Read Summary]	[Buy Article]

February 2005

	In Vivo: Biocompatibles: The Perils of Re-Inventing a Public Company	[Read Summary]	[Buy Article]
	In Vivo: ATI: Is This the Model for Device Development?	[Read Summary]	[Buy Article]
	In Vivo: Medtronic Sofamor Danek: The Trials of the Front Runner	[Read Summary]	[Buy Article]
	In Vivo: Cytokinetics Stays the Course	[Read Summary]	[Buy Article]
	In Vivo: The Buzz at JP Morgan--Devices: No Longer the Conference Stepchild	[Read Summary]	[Buy Article]
	In Vivo: The Buzz at JP Morgan--Biopharma: New Models Wanted	[Read Summary]	[Buy Article]
	In Vivo: Solvay Pharma: Dealing Its Way Into the Limelight	[Read Summary]	[Buy Article]
	Start-Up: Teasing Out Next-Generation Diabetes Drugs	[Read Summary]	[Buy Article]
	Start-Up: Devices for Age-Related Macular Degeneration	[Read Summary]	[Buy Article]

January 200